• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Abstract 236: Coronary Artery Procedures in the Cardiac Catheterization Laboratory After Overnight Call: Are Patients at Higher Risk? Session Title: Poster Session II
Conclusion: There were greater procedural complications when performed post-call compared to no post-call; however, when adjusting for significant baseline variables, there was no significant difference seen between groups. Taking into consideration factors that contributed to procedural complications most likely will improve patient outcomes.
Source: Circulation: Cardiovascular Quality and Outcomes - March 31, 2017 Category: Cardiology Authors: Boudoulas, K. D., Pederzolli, A., Nagaraja, H., Kahaly, O., Magorien, R., Mazzaferri, E. Tags: Session Title: Poster Session II Source Type: research

Abstract 244: Revision of the Consent Form for Coronary Angiography Procedures Session Title: Poster Session II
Conclusion: In a representative assessment of coronary angiography and PCI outcomes, some major complications are higher that those reported in international literature. Significant access site bleeding was low, likely explained by the high prevalence of radial procedures. Future iterations of the patient information sheet and consent form may be improved by providing personalized risks.
Source: Circulation: Cardiovascular Quality and Outcomes - March 31, 2017 Category: Cardiology Authors: Tavella, R., Halliday, L., Arstall, M., Worthley, M., Chew, D., Zeitz, C., Beltrame, J. F. Tags: Session Title: Poster Session II Source Type: research

Use of Contraindicated Antiplatelet Medications in the Setting of Percutaneous Coronary Intervention: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program Original Articles
Conclusions— In this national cohort, 18% of patients undergoing PCI had contraindications to common antiplatelet medications. Approximately 6% of those patients received a contraindicated medication with attendant bleeding risk, although this did not translate into significantly higher risk of 30-day mortality. Continued efforts to reduce contraindicated medication use may help avoid periprocedural complications.
Source: Circulation: Cardiovascular Quality and Outcomes - July 18, 2016 Category: Cardiology Authors: Barnes, G. D., Stanislawski, M. A., Liu, W., Baron, A. E., Armstrong, E. J., Ho, P. M., Klein, A., Maddox, T. M., Nallamothu, B. K., Rumsfeld, J. S., Tsai, T. T., Bradley, S. M. Tags: Platelets, Anticoagulants, Percutaneous Coronary Intervention, Stent, Quality and Outcomes Original Articles Source Type: research

Abstract 245: Cost Effectiveness and Safety of Abbreviated Eptifibatide Infusion in Veterans Undergoing Percutaneous Coronary Intervention Session Title: Poster Session II
Conclusion: In this real world cohort of patients undergoing PCI, an abbreviated 2 hour eptifibatide infusion after PCI was safe and had a cost savings of greater than 50% per patient, when compared with a standard 18 hour infusion. This approach is more cost-effective and should be considered in patients undergoing PCI who are not pretreated with dual antiplatelet therapy.
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Ghadban, R., Shah, A., Ampadu, J., Linneman, T., Thomas, J.-A., Forsberg, M., Stolker, J., Klein, A. Tags: Session Title: Poster Session II Source Type: research

Abstract 249: Economic Outcomes for Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention and Receiving Prasugrel or Ticagrelor: A Retrospective US Hospital Database Analysis Session Title: Poster Session II
Conclusion: Economic outcomes of ACS-PCI pts receiving pras were similar to ticag for the primary population with significant savings in total and medical costs for pts without prior TIA or stroke. These data indicate that ticag has no economic advantage compared with pras in routine clinical practice.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Molife, C., Frech-Tamas, F., Effron, M. B., DeKoven, M., Karkare, S., Zhu, Y. E., Larmore, C., Lu, J., Lee, W. C., Mc Collam, P., Marrett, E., Vetrovec, G. W. Tags: Session Title: Poster Session II Source Type: research

Abstract 320: Healthcare Resource Utilization Among Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention and Using Prasugrel or Ticagrelor: A Retrospective Database Analysis Session Title: Poster Session III
Conclusions: All-cause rehospitalizations at 30-and 90-days post discharge in ACS-PCI pts were non-inferior with pras vs. ticag in all 3 cohorts. Pras was associated with significantly lower risk for 90-day all-cause rehospitalizations compared with ticag in the label and core cohorts, which are the majority of pts receiving pras. Although there appears to be inherent bias and unmeasured confounders related to use of pras vs. ticag, these data show reductions in HCRU with pras compared with ticag in the real-world setting at 30- and 90-days post-discharge.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Molife, C., Effron, M. B., DeKoven, M., Karkare, S., Frech-Tamas, F., Larmore, C., Zhu, Y., Lu, J., Lee, W. C., Mc Collam, P., Marrett, E., Vetrovec, G. W. Tags: Session Title: Poster Session III Source Type: research

Abstract 340: Thirty-day Repeat Hospitalizations for Patients Treated with Prasugrel Compared to Ticagrelor following Acute Coronary Syndrome: Findings from a Large Hospital Charge Master Database Session Title: Poster Session III
Conclusion: Rehosp for MI, revasc or bleeding was non-inferior for pras compared to ticag at 30 days post discharge. Pts treated with pras had lower 30 day rehosp rates, particularly related to readmission for MI, compared with ticag. Although limited by selection bias, these results support the clinical utility of pras, regardless of cohort, to limit 30 day rehosp for pts undergoing PCI for ACS.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Vetrovec, G. W., Larmore, C., Molife, C., DeKoven, M., Karkare, S., Zhu, Y. E., Frech-Tamas, F., Lu, J., Lee, W. C., Mc Collam, P., Marrett, E., Effron, M. B. Tags: Session Title: Poster Session III Source Type: research